Loading patent…
AssigneeLeibniz-Institut FüR Polymerforschung E.V.
InventorsLucas Schirmer, UWE FREUDENBERG, CARSTEN WERNER, PASSANT ATTALAH
Estimating the term…
A method is disclosed for differentiated sequestration of substances of different substance groups A and B in a sulfated and/or sulfonated hydrogel while simultaneously releasing substances of substance group A or B from the sulfated and/or sulfonated hydrogel into a biofluid. The sulfated and/or sulfonated hydrogel is selected from hydrogels of Type 1, Type 2, Type 3, Type 4 and consist of uncharged and charged components. The charged components are characterized by calculating the number of sulfated or sulfonated groups per repeat unit divided by the molecular mass of the repeat unit, for each of Type 1, 2, 3 and 4. Swollen hydrogels have a different concentration of sulfated or sulfonated groups in mmol/ml for Type 1, Type 2, Type 3 and Type 4. The concentration of substances of each substance group A and group B in the biofluid is influenced by the selection of the type of hydrogel.
-17. (canceled)
Method for differentiated sequestration of substances of different substance groups A and B in a sulfated and/or sulfonated hydrogel from a biofluid, comprising:
The method of claim 1, wherein the number of sulfate and/or sulfonate groups per repeat unit of the at least one polymer divided by the molar mass of the repeat unit is 0.0050 mole/g for hydrogel type 1, of 0.0035 mole/g or 0.0038 mole/g for hydrogel type 2, of 0.0019 mole/g for hydrogel type 3, and of 0.0045 mole/g for hydrogel type 4, and wherein in the swollen state the hydrogels have a concentration of sulfate or sulfonate in mmole/ml of 0.12 for hydrogel type 1 and of 0.12 or 0.14 for hydrogel type 2 and of 0.06 for hydrogel type 3 and of 0.28 or 0.16 for hydrogel type 4.
The method of claim 1, wherein the substances in the biofluid whose concentration is controlled with hydrogel type 1 comprise at least one substance selected from the group consisting of bNGF, PDGF-BB, VEGF-A, eotaxin, GRO-alpha, IL-8, IP-10, MCP-1, MIP-1 alpha, MIP-1 beta, Rantes, SDF1-alpha, IFN-gamma, IL-12p40, IL-4, sclerostin and DKK1, with the at least one substance being depleted by more than 50% of an initial concentration of the at least one substance in the biofluid.
The method of claim 1, wherein in hydrogels of type 1 at least one of the substances selected from the group consisting of FGF-2, TGFb1, EGF, HGF, PLGF, GM-CSF, IL-1 beta, IL-10, IL-6 and/or TNF-alpha is bound only up to 50% of an initial concentration of the at least one substance in the hydrogel or released therefrom.
The method of claim 1, wherein the substances in the biofluid whose concentration is controlled with hydrogel type 2 comprise at least one substance selected from the group consisting of bNGF, PDGF-BB, VEGF-A, eotaxin, GRO-alpha, IL-8, IP-10, MCP-1, Rantes, SDF1-alpha, IFN-gamma, IL-12p40, IL-4 and DKK1 with the at least one substance being depleted by more than 50% of an initial concentration of the at least one substance in the biofluid.
The method of claim 1, wherein the substances in the biofluid whose concentration is controlled with hydrogel type 2 comprise at least one substance selected from the group consisting of FGF-2, TGFb1, EGF, HGF, PLGF, GM-CSF, IL-1 beta, IL-10, IL-6, TNF-alpha and sclerostin, wherein the substance are bound only up to 50% of an initial concentration of the at least one substance in the hydrogel or released therefrom.
The method of claim 1, wherein the substances in the biofluid whose concentration is controlled with hydrogel type 3 comprise at least one substance selected from the group consisting of bNGF, PDGF-BB, VEGF-A, eotaxin, GRO-alpha, IP-10, Rantes, SDF1-alpha, IFN-gamma and/or IL-4, with the at least one substance being depleted by more than 50% of an initial concentration of the at least one substance in the biofluid.
The method of claim 1, wherein the substances in the biofluid whose concentration is controlled with hydrogel type 3 comprise at least one substance selected from the group consisting of FGF-2, TGFb1, EGF, HGF, PLGF, IL-8, MCP-1, MIP-1 alpha, MIP-1 beta, GM-CSF, IL-1 beta, IL-10, IL-12p40, IL-6, TNF-alpha, sclerostin and DKK-1, wherein the at least one substance is bound only up to 50% of an initial concentration of the at least one substance in the hydrogel or released therefrom.
The method of claim 1, wherein the substances in the biofluid whose concentration is controlled with hydrogel type 4 comprise at least one substance selected from the group consisting of bNGF, PDGF-BB, VEGF-A, eotaxin, GRO-alpha, IL-8, IP-10, MCP-1, MIP-1 alpha, MIP-1 beta, Rantes, SDF1-alpha, IFN-gamma, IL-1 beta, IL-10, IL-12p40, IL-4, IL-6, and TNF-alpha, with the at least one substance being depleted by more than 60% of an initial concentration of the at least one substance in the biofluid.
The method of claim 1, wherein the substances in the biofluid whose concentration is controlled with hydrogel type 4 comprise at least one substance selected from the group consisting of EGF, PLGF and GM-CSF, wherein the substances are bound only up to 40% of an initial concentration of the at least one substance in the hydrogel or released therefrom.
The method of claim 1, wherein hydrogels of type 1, type 2, type 3 or type 4 are precharged with at least one substance whose concentration in the biofluid is to be controlled, whereafter the at least one substance is released from the hydrogel in parallel and independently to change a concentration of the at least one substance in the biofluid.
The method of claim 1, wherein the hydrogels are formed from multiphase materials, that are mixtures of hydrogels of types 1-4 of the hydrogel materials.
The method of claim 1, wherein the at least one polymer has a concentration of mole sulfate or sulfonate groups per mole of polymer of 60 to 80 in hydrogel type 1, of 30 to 75 in hydrogel type 2, of 10 to 30 in hydrogel type 3 and of 80 to 120 in hydrogel type 4, wherein a concentration of the at least one polymer in mmole/ml is 0.0015 to 0.0025 in hydrogel type 1, 0.0015 to 0.0030 in hydrogel type 2, 0.0010 to 0.0040 in hydrogel type 3, and 0.0018 to 0.0050 in hydrogel type 4.
The method of claim 14, wherein the at least one polymer has a concentration of mole sulfate or sulfonate groups per mole of polymer of 70.2 in hydrogel type 1 and of 48.4 or 75.0 in hydrogel type 2 and of 23.4 in hydrogel type 3 and of 90.0 in hydrogel type 4, wherein a concentration of the at least one polymer in the hydrogel in mmole/ml is 0.0018 for hydrogel type 1, 0.0025 or 0.0018 for hydrogel type 2, 0.0027 for hydrogel type 3, and 0.0031 or 0.0018 for hydrogel type 4, and the swollen hydrogels have a storage modulus of less than 20 kPa, with the concentration of sulfate or sulfonate groups in mmole per ml in the hydrogel being 0.12 for hydrogel type 1, 0.12 or 0.14 for hydrogel type 2, 0.06 for hydrogel type 3 and 0.28 or 0.16 for hydrogel type 4.
The method of claim 1, wherein the al least one molecule and the at least one polymer are crosslinked by reacting suitable functional groups on the at least one polymer and the at least one molecule selected from the group consisting of amines, thiols, carboxyls, anhydrides, maleimides, vinylsulfones, acrylates, hydroxyls, isocyanates, epoxides and aldehydes, and groups capable of forming noncovalent bonds based on electrostatic forces, hydrophobic interactions, hydrogen bonds or dipole interactions.
The method of claim 16, wherein at least one molecule and the at least one polymer are crosslinked via direct crosslinking by way of a small bifunctional crosslinking molecule having a molar mass UGB<500 g/mole.
Dependencies are inferred from the claim text.